Hookworms - A "Natural" Multiple Sclerosis Treatment?

More parasite treatments for MS.

Squirm here.

March 13, 2009 in complementary and alternative medicine , symptom management, treatment, worth following... | Permalink | Comments (2) | TrackBack

The Painful Truth

The Iraq war is a new kind of hell, with more survivors - but more maimed, shattered limbs - than ever. A revolution in battlefield medicine is helping them conquer the pain.

A technology worth following for those that experience pain.

More here.

April 28, 2005 in pain, research, worth following... | Permalink | Comments (0)

Balancing Act

Noise is the key to restoring the body's sense of equilibrium

I want these shoes! Interesting article on vibrating insoles and balance.

More here.

We are developing noise-based devices, such as vibrating insoles, to improve balance control in older adults and patients with diabetic neuropathy, stroke, Parkinson's disease, and multiple sclerosis, respectively.

More information and references  here.

April 28, 2005 in research, technology, treatment, worth following... | Permalink | Comments (0)

Serono plans multiple sclerosis treatment by inhalation


Serono of Switzerland is planning to expand its billion dollar multiple sclerosis franchise with a new version of interferon beta that would do away with the need for injections, reports Phil Taylor.

The company already sells an injectable drug for MS, Rebif (interferon beta 1a) and has small molecule, orally active drugs in its pipeline. These could now been joined by an inhaleable formulation that would provide a more patient-friendly alternative to the current injectable drugs for MS, and could improve efficacy.

Inhale here.

March 31, 2005 in rebif, research, treatment, worth following... | Permalink | Comments (0)

Serono Completes Patient Enrollment in Rebif(R) Versus Copaxone(R) Comparative Clinical Trial

Serono (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in a multi-national Rebif(R) (interferon beta-1a) versus Copaxone(R) (glatiramer acetate) comparative clinical trial. This two-year trial is designed to compare the efficacy of the two therapies in patients with relapsing remitting multiple sclerosis (RRMS), who were previously untreated with disease modifying therapies.

More here.

January 5, 2005 in copaxone, rebif, research, worth following... | Permalink | Comments (0)

Gene linked to myelin repair in the brain

In a study published in the December 17 issue of the journal Science, scientists from the Centre for Brain Repair and the School of Veterinary Medicine at the University of Cambridge and the Dana-Farber Institute at Harvard University, report that the gene Olig 1, thought to aid the development of certain brain cells, is essential for the myelin-repairing process in adults with Central Nervous System (CNS) diseases like Multiple Sclerosis (MS).

More here.

December 20, 2004 in myelin, research, worth following... | Permalink | Comments (0)

IVAX, Serono say oral cladribine trials for MS positive

The Swiss pharmaceuticals group Serono and its US partner IVAX Corp. posted positive results from two clinical trials with an oral formulation of cladribine, a potential new treatment for multiple sclerosis (MS).

"This is a major step in the development of the first oral disease modifying treatment for multiple sclerosis."

That would be nice.

Swallow here.

March 23, 2004 in follow the money..., research, worth following... | Permalink | Comments (0)

New Data Challenge Theories of Multiple Sclerosis

A new view of multiple sclerosis (MS) may arise from the first extensive study of brain tissue from the earliest hours during a bout of the disease. The results, published February 23, 2004, in the advance on-line edition of the Annals of Neurology, suggest that the earliest event is not, as previously believed, a misguided immune system attack on a brain substance called myelin.

Instead, the first event appears to be the death of the brain cells that produce myelin, triggering a subsequent immune system mop-up operation to clean up the cells and the myelin, said author John W. Prineas, MBBS, of the University of Sydney in Australia.

More here.

February 22, 2004 in research, worth following... | Permalink | Comments (0)

Base gets 'Dirty Dozen' anti-award

MS and exposure to environmental toxins seems to be something that comes up often.

At the press conference, Rockland resident Liz Tomolillo, who has multiple sclerosis, stressed the number of cases of multiple sclerosis near the base. She held up a map of wells and cases of illness near the base.

The state Department of Public Health (DPH) is currently doing a study to determine whether there are high levels of multiple sclerosis around the base and, if so, if occurrence of the disease is associated with contamination on the 1,450-acre site. This study is expected to be completed next fall.
There are 12 Superfund sites on the base.

More here.

December 12, 2003 in environment, worth following... | Permalink | Comments (0)

Tovaxin, an MS vaccine

TovaxinTM is a novel therapeutic vaccine that parallels the concept of autologous cancer vaccines. Instead of modifying cancerous cells, Tovaxin TM consists of modified autoreactive T cells. Modification of these cells during the vaccine production process causes them to elicit an immune response when injected back into the patient. This immune response is directed against T cells within the patient that are self-reactive with myelin. This immune response, directed against a specific subset of autoreactive T cells, greatly reduces the number of these autoreactive cells in MS patients. TovaxinTM has considerable potential because it attacks the underlying cause of MS rather than just addressing its symptoms.

Read more here.

December 8, 2003 in research, worth following... | Permalink | Comments (9)